Evrofarma Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Evrofarma.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Food earnings growth10.1%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Subdued Growth No Barrier To Evrofarma SA (ATH:EVROF) With Shares Advancing 30%

Feb 29
Subdued Growth No Barrier To Evrofarma SA (ATH:EVROF) With Shares Advancing 30%

Evrofarma SA (ATH:EVROF) Stock Rockets 33% But Many Are Still Ignoring The Company

Jan 06
Evrofarma SA (ATH:EVROF) Stock Rockets 33% But Many Are Still Ignoring The Company

Returns On Capital At Evrofarma (ATH:EVROF) Have Stalled

Jan 05
Returns On Capital At Evrofarma (ATH:EVROF) Have Stalled

Evrofarma (ATH:EVROF) Has A Somewhat Strained Balance Sheet

Dec 01
Evrofarma (ATH:EVROF) Has A Somewhat Strained Balance Sheet

Here's What's Concerning About Evrofarma's (ATH:EVROF) Returns On Capital

Sep 15
Here's What's Concerning About Evrofarma's (ATH:EVROF) Returns On Capital

Is Evrofarma (ATH:EVROF) Using Too Much Debt?

May 27
Is Evrofarma (ATH:EVROF) Using Too Much Debt?

We Think That There Are Issues Underlying Evrofarma's (ATH:EVROF) Earnings

Oct 04
We Think That There Are Issues Underlying Evrofarma's (ATH:EVROF) Earnings

Returns On Capital At Evrofarma (ATH:EVROF) Paint A Concerning Picture

May 19
Returns On Capital At Evrofarma (ATH:EVROF) Paint A Concerning Picture

Should Evrofarma SA (ATH:EVROF) Focus On Improving This Fundamental Metric?

Feb 22
Should Evrofarma SA (ATH:EVROF) Focus On Improving This Fundamental Metric?

Be Wary Of Evrofarma (ATH:EVROF) And Its Returns On Capital

Dec 29
Be Wary Of Evrofarma (ATH:EVROF) And Its Returns On Capital

Is Evrofarma SA's (ATH:EVROF) 2.2% ROE Worse Than Average?

Nov 22
Is Evrofarma SA's (ATH:EVROF) 2.2% ROE Worse Than Average?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Evrofarma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

ATSE:EVROF - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/202349303N/A
3/31/202347202N/A
12/31/202245102N/A
9/30/2022420-11N/A
6/30/202239-1-30N/A
3/31/202238-1-40N/A
12/31/2021370-4-1N/A
9/30/2021361-3-1N/A
6/30/2021361-2-1N/A
3/31/2021351-10N/A
12/31/202034111N/A
9/30/202033112N/A
6/30/202032022N/A
3/31/202033012N/A
12/31/201933012N/A
9/30/201934001N/A
6/30/201935101N/A
3/31/201934112N/A
12/31/201833112N/A
9/30/201832123N/A
6/30/201831123N/A
3/31/201831123N/A
12/31/201731123N/A
9/30/201731023N/A
6/30/201730023N/A
3/31/2017300N/A2N/A
12/31/2016290N/A1N/A
9/30/2016280N/A0N/A
6/30/2016280N/A1N/A
3/31/2016300N/A1N/A
12/31/2015301N/A1N/A
9/30/2015290N/A2N/A
6/30/2015280N/A2N/A
3/31/2015260N/A1N/A
12/31/2014250N/A1N/A
9/30/2014250N/A0N/A
6/30/2014250N/A0N/A
3/31/2014240N/A0N/A
12/31/2013230N/A0N/A
9/30/201322-1N/A1N/A
6/30/201322-2N/A1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if EVROF's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if EVROF's earnings are forecast to grow faster than the Greek market

High Growth Earnings: Insufficient data to determine if EVROF's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if EVROF's revenue is forecast to grow faster than the Greek market.

High Growth Revenue: Insufficient data to determine if EVROF's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if EVROF's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.